目的 探讨复方血栓通胶囊联合复方樟柳碱注射液治疗青光眼视神经萎缩的临床疗效。方法 将2024年3月—2025年12月在新疆医科大学第一附属医院就诊的青光眼视神经萎缩患者共83例纳入研究，按随机数字表法分为对照组（41例）和治疗组（42例）。对照组患侧颞浅动脉旁皮下注射复方樟柳碱注射液，2 mL/次，1次/d。治疗组在对照组基础上口服复方血栓通胶囊，1.5 g/次，3次/d。评估两组治疗6周的疗效。比较患者的治疗效果、视力参数、眼底血流动力学、视神经功能、血清指标。结果 治疗组的总有效率为88.10%，对照组的总有效率为68.29%，总有效率的组间差异显著（P＜0.05）。两组治疗后患侧的视力值明显提高，缺损度、总灰度值均明显降低（P＜0.05），且治疗组治疗后患侧的视力值明显高于对照组，缺损度、总灰度值低于对照组（P＜0.05）。两组治疗后的阻力指数（RI）、搏动指数（PI）明显降低，舒张末期流速（EDV）明显升高（P＜0.05）；治疗组治疗后的RI、PI低于对照组，EDV高于对照组（P＜0.05）。两组治疗后P100振幅明显升高，潜伏期明显降低（P＜0.05）；治疗组治疗后P100振幅高于对照组，潜伏期低于对照组（P＜0.05）。两组治疗后的促红细胞生成素（EPO）、内皮素-1（ET-1）明显降低，白细胞介素-12（IL-12）明显升高（P＜0.05）；治疗组治疗后的EPO、ET-1低于对照组，IL-12高于对照组（P＜0.05）。结论 复方血栓通胶囊联合复方樟柳碱注射液具有治疗青光眼视神经萎缩的临床疗效，可提高视力，改善视神经功能和血流动力学，降低炎症反应。

Objective To investigate the clinical efficacy of Compound Xueshuantong Capsules combined with Compound Anisodine Hydrobromide Injection in treatment of optic nerve atrophy in glaucoma. Methods 83 Patients with optic nerve atrophy in glaucoma who visited the First Affiliated Hospital of Xinjiang Medical University from March 2024 to December 2025 were selected and divided into a control group (41 cases) and a treatment group (42 cases) using a random number table method. The control group received sc Compound Anisodine Hydrobromide Injection at a dose of 2 mL/time, once daily, adjacent to the superficial temporal artery on the affected side. The treatment group received oral administration of Compound Xueshuantong Capsules at a dose of 1.5 g/time, three times daily, in addition to the treatment in the control group. The efficacy of the two groups was evaluated after 6 weeks of treatment. The treatment efficacy, visual parameters, fundus hemodynamics, optic nerve function, and serum indicators of patients were compared. Results The total effective rate of the treatment group was 88.10%, while the total effective rate of the control group was 68.29%, and the difference in total effective rate between two groups was significant (P < 0.05). After treatment, the visual acuity was significantly improved in two groups, but defect degree, and total grayscale value were decreased (P < 0.05), and the visual acuity in the treatment group was significantly higher than that in the control group, but defect degree total and grayscale value were significantly lower (P < 0.05). After treatment, the resistance index (RI) and pulsatility index (PI) of two groups significantly decreased, while the end diastolic flow velocity (EDV) significantly increased (P < 0.05). The RI and PI of the treatment group were lower than those of the control group after treatment, but the EDV was higher than that of the control group (P < 0.05). After treatment, the amplitude of P100 significantly increased but the latency significantly decreased in two groups (P < 0.05). After treatment, the amplitude of P100 in the treatment group was higher than that in the control group, but the latency was lower than that in the control group (P < 0.05). After treatments, the serum levels of erythropoietin (EPO) and endothelin-1 (ET-1) were significantly reduced, while the serum levels of interleukin-12 (IL-12) were significantly increased (P < 0.05). The serum levels of EPO and ET-1 in the treatment group were lower than those in the control group after treatment, while serum levels of IL-12 were higher than those in the control group (P < 0.05). Conclusion The combination of Compound Xueshuantong Capsules and Compound Anisodine Hydrobromide Injection has clinical efficacy in treating optic nerve atrophy in glaucoma, which can improve vision, improve optic nerve function and hemodynamics, and reduce inflammatory reactions

R988.1

新疆医科大学第一附属医院青年科研启航专项基金项目(2023YFY-QKHL-03)